Evaluation of cartilage and bone degradation in a murine collagen antibody-induced arthritis model

Scandinavian Journal of Immunology

Volumn 67, Issue 3, 2008, Pages 304-312

  Oestergaard, S ^a   Rasmussen, K E ^a   Doyle, N ^b   Varela, A ^b   Chouinard, L ^b   Smith, S Y ^a   Qvist, P ^a   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; DEXAMETHASONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTHRITIS; ARTICLE; BONE DEFECT; CARTILAGE DEGENERATION; CHONDROPROTECTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; MALE; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; SCORING SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; CARTILAGE; COLLAGEN TYPE II; DEXAMETHASONE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38849122704     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.02060.x     Document Type: Article

References (44)

1. Feldmann M, Brennan FM, Maini R. Rheumatoid arthritis. Cell 1995 85 : 307 10.
2. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003 25 : 3 18.
3. Smolen JS, Steiner G. Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis. Arthritis Rheum 2001 44 : 2218 20.
4. Staines NA, Wooley PH. Collagen arthritis - what can it teach us? Br J Rheumatol 1994 33 : 798 807.
5. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005 12 : 167 81.
6. Nandakumar KS, Holmdahl R. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 2006 8 : 223.
7. Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CIAI) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods 2005 304 : 126 36.
8. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. J Exp Med 1981 154 : 688 700.
9. Terato K, Hasty KA, Cremer MA, Stuart JM, Townes AS, Kang AH. Collagen-induced arthritis in mice. J Exp Med 1985 162 : 637 46.
10. Terato K, Harper DS, Griffiths MM et al. Collagen-induced arthritis in mice: synergic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 1995 22 : 134 47.
11. Backlund J, Nandakumar KS, Bockermann R, Mori L, Holmdahl R. Genetic control of tolerance to type II collagen and development of arthritis in an autologous collagen-induced arthritis model. J Immunol 2003 171 : 3493 9.
12. Nandakuamr KS, Holmdahl R. Arthritis induced with cartilage-specific antibodies is IL-4-dependent. Eur J Immunol 2006 36 : 1608 18.
13. Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice. Am J Pathol 2003 163 : 1827 37.
14. Kagari T, Doi H, Shimozato T. The importance of IL-1β and TNF-α, and the non-involvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002 169 : 1459 66.
15. Nandakumar KS, Backlund J, Vestberg M, Holmdahl R. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enchanced by CII-reactive T cells. Arthritis Res Ther 2004 6 : R544 50.
16. Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006 147 : S258 68.
17. Oestergaard S, Chouinard L, Doyle N et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage 2006 14 : 670 9.
18. Terato K, Shimozuru Y, Katayama K et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 1990 33 : 1493 1500.
19. Cook AD, Gray R, Ramshaw J, Mackay IR, Rowley M. Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res Ther 2004 6 : R477 483.
20. Johansson ACM, Vestberg M, Holmdahl R. Non-Major histocompatibility complex depend variations in lymphocyte activity between inbred mouse strains susceptible to various autoimmune diseases. Scand J Immunol 2000 52 : 21 9.
21. Wang Y, Burnier M, Detrick B, Hooks JJ. Genetic predisposition to coronavirus-induced retinal disease. Invest Ophthalmol Vis Sci 1996 37 : 250 4.
22. Sedegah M, Charoenvit Y, Aguiar J et al. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun 2004 5 : 553 61.
23. Freeman GL, Colston JT, Zabalgoitia M, Chandraskar B. Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis. Am J Physiol Heart Circ Physiol 1998 274 : 249 58.
24. Feldmann M, Brennan FM, Williams RO, Woody JN, Mainin RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004 18 : 59 80.
25. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997 107 : 507 12.
26. Guedez YB, Whittington KB, Clayton JL et al. Genetic ablation of interferon-γ up-regulates interleukin-1β expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 2001 44 : 2413 24.
27. Sims NA, Green JR, Glatt M et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004 7 : 2338 46.
28. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002 61 (Suppl. II ii84 86.
29. Goldring SR. The final pathogenetic steps in focal bone erosions in rheumatoid arthritis. Ann Rheum Dis 2000 59 (Suppl. 1 i72 4.
30. Barck KH, Lee WP, Diehl LJ et al. Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis. Arthritis Rheum 2004 50 : 3377 86.
31. Nishida S, Tsurukami H, Sakai A et al. Stage-dependent changes in trabecular bone turnover and osteogenic capacity of marrow cells during development of type II collagen-induced arthritis in mice. Bone 2002 30 : 872 9.
32. Kliwinski C, Kukral D, Postelnek J et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J Autoimmun 2005 25 : 165 71.
33. Yamane I, Hagino H, Okano T, Enokida M, Yamasaki D, Teshima R. Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis. Arthrtis Rheum 2003 48 : 1732 41.
34. Oestergaard S, Chouinard L, Doyle N, Smith SY, Tanko LB, Qvist P. Early elevation in circulating levels of C-telopeptides of type II collagen predicts structural damage in articular cartilage in the rodent model of collagen-induced arthritis. Arthritis Rheum 2006 54 : 2886 90.
35. Oestergaard S, Sondergaard BC, Hoegh-Andersen P et al. Effects of ovariectomy and estrogen therapy of type II collagen degradation and structural integrity of articular cartilage in rats: implication of the time of initiation. Arthritis Rheum 2006 54 : 2441 51.
36. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodymanics of systemically administrated glucocorticoids. Clin Pharmacokinet 2005 44 : 61 98.
37. Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-α secretion. Inflamm Res 1997 46 : 447 51.
38. Larsson E, Erlandsson HH, Larsson A, Mansson B, Saxne T, Klareskog L. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology (Oxford) 2004 43 : 428 34.
39. Kang I, Lee W, Lee Y. Modulation of collagen-induced arthritis by IL-4 and dexamethasone: the synergic effect of IL-4 and dexamethasone on the resolution of CIA. Immunopharmacology 2000 49 : 317 24.
40. Cuzzocrea S, Mazzon E, Di Paola R et al. Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. Arthritis Rheum 2005 52 : 1929 40.
41. Boling EP. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Clin Ther 2004 26 : 1 14.
42. Kirwan JR. The effect of glucocorticoids on the joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995 333 : 142 6.
43. Wassenberg S, Rau R, Stenfeld P, Zeidler H. Very low-dose prednizolone in early rheumatoid arthritis retards radiographic progression over 2 years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005 52 : 3371 80.
44. Svensson B, Boonen A, Albertsson K, van der Hejde D, Keller C, Hafstrom I. Low-dose prednizolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a 2-year randomized trial. Arthritis Rheum 2005 52 : 3360 70.